On the stock market since 2012, it operates in the world of health and science. It has 5 employees. Now — the numbers.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 86% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 16/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 24/100. For a turnaround signal, the stock first needs to close the gap with the market.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 37/100.
On our five-subject report card, GRCE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: GRCE is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.